Brief: Enanta Pharmaceuticals Reports Positive Phase 2b Results for RSV Drug Zelicapavir
29/09/2025 11:38
Sept 29 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O: ENANTA PHARMACEUTICALS REPORTS POSITIVE TOPLINE RESULTS FROM ITS PHASE 2B STUDY OF ZELICAPAVIR FOR THE TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) IN HIGH-RISK ADULTS ENANTA PHARMACEUTICALS INC - LOWER HOSPITALIZATION RATE FOR ZELICAPAVIR-TREATED PATIENTS ENANTA PHARMACEUTICALS INC: STUDY SHOWED ZELICAPAVIR DEMONSTRATED FAVORABLE SAFETY PROFILE & WAS WELL-TOLERATED Source text: ID:nBw9HwtXWa Further company coverage: ENTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates